悦康药业股价连续7天下跌累计跌幅19.23%，华富基金旗下1只基金持52万股，浮亏损失271.44万元

Group 1 - The core point of the news is that Yuyuan Pharmaceutical has experienced a continuous decline in stock price, dropping 19.23% over the past seven days, with a current price of 21.93 yuan per share and a market capitalization of 9.869 billion yuan [1] - Yuyuan Pharmaceutical focuses on the research and production of high-end chemical drugs, with significant revenue contributions from cardiovascular drugs (55.67%), anti-infection drugs (20.88%), and diabetes medications (4.85%) [1] - The company's main products include Ginkgo biloba extract injection, Tianma injection, Lansoprazole injection, and Metformin sustained-release tablets, which have substantial revenue contributions and growth potential [1] Group 2 - Huafu Fund has a significant holding in Yuyuan Pharmaceutical, with its Huafu Health and Entertainment Flexible Allocation Mixed A fund holding 520,000 shares, representing 6.13% of the fund's net value [2] - The fund has incurred a floating loss of approximately 271.44 thousand yuan during the seven-day decline, with a current year loss of 1.6% and a one-year return of 21.04% [2] - The fund manager, Liao Qingyang, has been in position for 4 years and 87 days, with the fund's total asset size at 838 million yuan [3]